Biologic Therapeutic Articles & Analysis
10 articles found
The versatility of CHO cells extends to their capacity to express complex proteins, including glycoproteins, which are often crucial for the biological activity of therapeutic agents. This ability is vital because many therapeutic proteins require specific glycosylation patterns to be effective and to avoid immune recognition. ...
Introduction Good Manufacturing Practice (GMP) cell banks play a crucial role in the biopharmaceutical industry, serving as foundational repositories of cell lines used for the production of therapeutic biological products. Characterization of these cell banks is essential to ensure the safety, efficacy, and consistency of the biopharmaceuticals derived from ...
Knockin cell line generation represents a pivotal advancement in genetic engineering, providing vital tools for biological research and therapeutic development. This process involves the integration of specific DNA sequences into precise loci within the genome, allowing scientists to explore gene function, model diseases, and develop new treatments. ...
Peptidomimetics are structural analogs of peptides or proteins that mimic their biological activities. They are designed to overcome limitations associated with peptides, such as poor stability and bioavailability by preserving or enhancing their functions. ...
Fc-Fusion Glycosylation and Its Biological Significance Glycosylation Therapeutic monoclonal antibodies (mAb) or mAb variant molecules such as Fc-Fusion have an N-linked glycan coherent sequence of (Asn)-X-Ser/Thr (where X is any amino acid except Pro) at the Asn297 position of the heavy chain of the constant CH2 domain, and some mAb also have additional ...
Scientists continuously face pressure to purify biologics like protein therapeutics with maximum yield while minimizing cost and developing processes as quickly as possible. ...
During lead discovery, an intensive search ensues to find a drug-like small molecule or biological therapeutic, initially a hit that, through further validation and evolution, can become a development candidate that will progress into preclinical and, if successful, into clinical development and ultimately be a marketed medicine. ...
Different from traditional small molecule inhibitors and antagonists, protein degradation technology has developed rapidly in recent years because of its ability to induce the degradation of therapeutic target proteins, providing a new idea for the development of new drugs. ...
In the future, new strategies based on nanofluidic chip technology to achieve exosome loading are expected to develop into a platform-type tool to load different exogenous substances with biological significance and clinical therapeutic effects into exosomes and get more applications in biological research and cell-free ...
Therefore, recombinant glycoprotein biologics intended for human therapeutic applications are usually manufactured in mammalian cell systems, which have protein glycosylation pathways that can provide terminal sialylation (Walsh, 2010). ...